Phase 1/2a Clinical Trial of PR001 (LY3884961) in Patients With Parkinson's Disease With at Least One GBA1 Mutation (PROPEL)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT04127578 |
|
Recruitment Status :
Recruiting
First Posted : October 15, 2019
Last Update Posted : May 6, 2023
|
Sponsor:
Prevail Therapeutics
Collaborator:
Eli Lilly and Company
Information provided by (Responsible Party):
Prevail Therapeutics
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Recruitment Status : | Recruiting |
|---|---|
| Estimated Primary Completion Date : | June 2029 |
| Estimated Study Completion Date : | June 2029 |